Cayman SARS-CoV-2 Spike Glycoprotein S2 Subunit (recombinant)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the Betacoronavirus genus, and the causative agent of COVID-19.^,,,, The SARS-CoV-2 spike glycoprotein, also known as the surface glycoprotein, is a viral structural protein encoded by the S gene in SARS-CoV-2 RNA. It is composed of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.^, The C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes, contains a fusion peptide (FP) and two heptad repeats (HRs), as well as transmembrane and cytoplasmic domains.^, Upon insertion of the FP in the target cell membrane, the HRs form a six-helical bundle (6-HB) that enables SARS-CoV-2 to fuse with the target cell. The SARS-CoV-2 spike glycoprotein S2 subunit increases amyloid-β (1-40) (Aβ40) and Aβ42 levels in primary mouse neuron culture supernatants and the number of hippocampal and cortical Aβ plaques in APPswe/PSEN1dE9 transgenic mice. Caymans SARS-CoV-2 Spike Glycoprotein S2 Subunit (recombinant) protein is a disulfide-linked homodimer. The reduced monomer, composed of the SARS-CoV-2 spike glycoprotein S2 subunit (amino acids 686-1,213) fused to mouse IgG1 Fc at its C-terminus, consists of 762 amino acids and has a calculated molecular weight of 84.3 kDa.

WARNING This product is not for human or veterinary use.